Abstract: Stimulation using EA of LI-4, LI-11, GV-14 and GV-20 in humans, horses, and rodents results in mobilization of MSCs into systemic circulation. Methods are provided for increasing mesenchymal stem cells in the circulating blood of a mammal by contacting acupuncture points LI-4, LI-11, GV-14, and GV-20 of the mammal with a therapeutically effective amount of EA stimulation to mobilize MSCs into the circulating blood of the mammal. Methods for treating damaged tissue, specifically damaged tendons are also provided. Isolated mesenchymal stem cells made according to these methods, methods of isolated them, and stem cell banks that store them are also provided.

Abstract: Stimulation using EA of LI-4, LI-11, GV-14 and GV-20 in humans, horses, and rodents results in mobilization of MSCs into systemic circulation. Methods are provided for increasing mesenchymal stem cells in the circulating blood of a mammal by contacting acupuncture points LI-4, LI-11, GV-14, and GV-20 of the mammal with a therapeutically effective amount of EA stimulation to mobilize MSCs into the circulating blood of the mammal. Methods for treating damaged tissue, specifically damaged tendons are also provided. Isolated mesenchymal stem cells made according to these methods, methods of isolated them, and stem cell banks that store them are also provided.

Abstract: According to one embodiment, a nutritional supplement for suppressing an appetite while maintaining muscle mass of a subject during weight loss is provided. The nutritional supplement includes beta-hydroxy beta-methylbutyric acid (HMB), chromium, and Caralluma fimbriata.

Abstract: According to one embodiment, a nutritional supplement for suppressing an appetite while maintaining muscle mass of a subject during weight loss is provided. The nutritional supplement includes beta-hydroxy beta-methylbutyric acid (HMB), chromium, and Caralluma fimbriata.

Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-? expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-? blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-? blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which PAI-1 expression and/or activity has been transiently blocked. Other methods involve the administration of a PAI-1 blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a PAI-1 blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-? expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-? blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-? blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate.

Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides a method and compositions for preventing and/or treating abnormal vascular proliferation in a human infant where the method involves enterally administering arginine and glutamine to the infant in about equimolar amounts to provide a total amount of arginine and glutamine that is effective to prevent or treat the abnormal vascular proliferation. Arginyl-glutamine dipeptide was shown to be an advantageous form in which to provide the two amino acids.

Abstract: The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine?pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

Abstract: The invention provides methods of detection, prevention, amelioration, and treatment for angiogenesis, including angiogenesis associated with colon cancer and glioma. The methods comprise the use of an anti-A2B antibody.

Abstract: Disclosed are ribozymes, as well as compositions, vectors, virus particles, host cells, and therapeutic kits comprising them useful in the treatment of diseases of the eye, including retinopathy and macular degeneration, and the amelioration of symptoms of such diseases including loss of vision, retinitis, and blindness.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution, and in particular, into infant formulations.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides novel methods and materials for treating diabetic retinopathy. One embodiment of the subject invention involves the co-administration of a somatostatin, or analogue thereof, and a thryoid-related substance such as thyroxine. Somatostatin or thyroid-related substance can be administered in combination, or separately through the same or different modes of administration.

Abstract: A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-&bgr;-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.

Abstract: The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine⇄pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts.